Atossa Genetics (NASDAQ:ATOS) Shares to Reverse Split on Monday, February 2nd

Atossa Genetics Inc. (NASDAQ:ATOS)’s stock is set to reverse split on Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 30th.

Atossa Genetics Stock Down 10.0%

ATOS stock opened at $0.62 on Thursday. Atossa Genetics has a twelve month low of $0.55 and a twelve month high of $1.29. The stock has a market capitalization of $79.62 million, a price-to-earnings ratio of -2.57 and a beta of 1.09. The firm’s fifty day simple moving average is $0.70 and its two-hundred day simple moving average is $0.80.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Wednesday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). As a group, equities research analysts expect that Atossa Genetics will post -0.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ATOS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Ascendiant Capital Markets boosted their price objective on Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a report on Monday, December 8th. Finally, Zacks Research lowered Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ATOS. Ameriprise Financial Inc. purchased a new stake in shares of Atossa Genetics in the 2nd quarter worth $2,468,000. Jane Street Group LLC bought a new stake in shares of Atossa Genetics in the second quarter valued at about $381,000. Y Intercept Hong Kong Ltd purchased a new stake in Atossa Genetics in the second quarter worth about $321,000. Qube Research & Technologies Ltd lifted its stake in Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares during the period. Finally, GSA Capital Partners LLP grew its holdings in Atossa Genetics by 509.0% during the 3rd quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock worth $269,000 after acquiring an additional 259,725 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.